Kinetics of antibodies against pneumococcal proteins and their relationship to nasopharyngeal carriage in the first two months of life. by Mendy, Awa L et al.
Mendy, AL; Agbla, SC; Odutola, AA; Antonio, M; Greenwood, BM;
Sutherland, JS; Ota, MOC (2017) Kinetics of antibodies against pneu-
mococcal proteins and their relationship to nasopharyngeal carriage
in the first two months of life. Plos One, 12 (10). ISSN 1932-6203
DOI: https://doi.org/10.1371/journal.pone.0185824
Downloaded from: http://researchonline.lshtm.ac.uk/4550566/
DOI: 10.1371/journal.pone.0185824
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE
Kinetics of antibodies against pneumococcal
proteins and their relationship to
nasopharyngeal carriage in the first two
months of life
Awa L. Mendy1, Schadrac C. Agbla1,2, Aderonke A. Odutola1, Martin Antonio1,3,4, Brian
M. Greenwood3, Jayne S. Sutherland1, Martin O. C. Ota1,5*
1 Vaccines & Immunity Theme, Medical Research Council Unit, Fajara, The Gambia, 2 Faculty of
Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United
Kingdom, 3 Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine,
London, United Kingdom, 4 Division of Microbiology & Immunity, Warwick Medical School, University Of
Warwick, Coventry, United Kingdom, 5 Health Information and Knowledge Management, Health Systems
and Services Cluster, WHO Regional Office for Africa, Brazzaville, Congo
* otama@who.int
Abstract
Introduction
The currently used Streptococcus pneumoniae vaccines have had a significant impact on
the pneumococcal diseases caused by the serotypes they cover. Their limitations have stim-
ulated a search for alternate vaccines that will cover all serotypes, be affordable and effec-
tive in young children. Pneumococcal protein antigens are potential vaccine candidates that
may meet some of the shortfalls of the current vaccines. Thus, this study aimed to determine
the relationship between antibodies against pneumococcal protein antigens and nasopha-
ryngeal carriage in infants.
Methods
One hundred and twenty mother-infant pairs were enrolled into the study. They had naso-
pharyngeal swabs(NPS) taken at birth and every two weeks for the first eight weeks after
delivery, and blood samples were obtained at birth and every four weeks for the first eight
weeks after delivery. Nasopharyngeal carriage of S. pneumoniae was determined from the
NPS and antibodies against the pneumococcal proteins CbpA, PspA and rPly were mea-
sured in the blood samples.
Results
The S. pneumoniae carriage rate in infants increased to that of mothers by eight weeks of
age. The odds of carriage in infants was 6.2 times (95% CI: 2.0–18.9) higher when their
mothers were also carriers. Bacterial density in infants was lower at birth compared to their
mothers (p = 0.004), but increased with age and became higher than that of their mothers at
weeks 4 (p = 0.009), 6 (p = 0.002) and 8 (p<0.0001). At birth, the infants’ antibodies against
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CbpA, and rPly pneumococcal protein antigens were similar, but that of PspA was lower
(p<0.0001), compared to their mothers. Higher antibody concentrations to CbpA [OR (95%
CI): 0.49 (0.26–0.92, p = 0.03)], but not PspA and rPly, were associated with protection
against carriage in the infants.
Conclusion
Naturally induced antibodies against the three pneumococcal protein antigens were trans-
ferred from mother to child. The proportion of infants with nasopharyngeal carriage and the
bacterial density of S. pneumoniae increased with age within the first eight weeks of life.
Higher concentrations of antibodies against CbpA, but not PspA and rPly, were associated
with reduced risk of nasopharyngeal carriage of S. pneumoniae in infants.
Introduction
The recent estimate of the number of deaths from pneumonia in children under five years is
believed to be about 900,000 about a half of which is believed to be due to pneumococcal dis-
ease, and mainly in developing countries.[1] The causative agent, Streptococcus pneumoniae
(the pneumococcus), has over 90 serotypes and normally inhabits the nasopharynx, a state that
is assumed to be a precursor of disease, as shown by the association between high rates of
pneumococcal carriage and incidence of IPD.[2,3]
Currently, there are two types of pneumococcal vaccines, capsular polysaccharide (PS) and
polysaccharide conjugate vaccines (PCV). PS vaccines are poorly immunogenic in children
below the age of two years, fail at any age to generate immunological memory, and do not pro-
vide herd immunity, making them of limited use for protection of young children. In contrast,
PCV are immunogenic in young children and protect against IPD as well as carriage.[4,5]
Although PCV are effective, their efficacy is limited to the serotypes contained in the vaccines
[6] and there is evidence of an increase in the prevalence of carriage and IPD caused by non-
vaccine serotypes in populations where PCV have been used widely.[7] The complex chemistry
involved has limited attempts to increase the number of serotypes contained in a vaccine for-
mulation. Nonetheless, there are several vaccine formulations with additional serotypes cur-
rently under evaluation. Moreover, PCV are expensive to produce and attempts to reduce cost
by using alternate, reduced dosing schedules have so far been inconclusive. [8–10]
The limitations of the available pneumococcal vaccines have warranted a search for alter-
nate vaccines, including those based on pneumococcal protein antigens that are conserved
across all serotypes and likely to be immunogenic and cheap. A number of such antigens are
currently being investigated as potential vaccine candidates including pneumococcal surface
protein A (PspA), pneumolysin (Ply), and choline-binding protein A (CbpA) [11]. Studies in
mice have shown that vaccination with these proteins can protect against disease as well as
nasopharyngeal carriage of the pneumococcus.[12,13] Vaccination with a single recombinant
PspA variant in humans elicited broadly cross-reactive antibodies to heterologous PspA mole-
cules.[14] In Sweden, it has been shown in a phase 1 trial that two doses of a tri-component
PhtD-dPly-PD vaccine was immunogenic in adults, inducing increases in antibody concentra-
tions and antigen-specific Th1- and Th17-directed cell-mediated immune responses after each
dose. [15] A single dose of a protein-based pneumococcal vaccine containing polysaccharide
conjugates of 10 pneumococcal serotypes combined with pneumolysin toxoid(dPly) and
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pneumococcal histidine triad protein D(PhtD) (PHiD-CV/dPly/PhtD-30) in 2–4 years old
Gambian children, not previously vaccinated against S. pneumoniae, was well tolerated and
immunogenic.[16] However, in the same setting, this vaccine had no impact on pneumococcal
nasopharyngeal carriage in infants, regardless of protein dose or schedule.[17]
Demonstration of a correlation between anti-capsular antibody concentration and clinical
efficacy has facilitated the evaluation of new PCV. [18–20]. However, investigations of the rela-
tionship between antibodies to protein antigens and nasopharyngeal carriage, a first step in the
progression to IPD, have yielded contradictory results. [21, 22]. Therefore, this study aimed to
evaluate the kinetics of antibodies to three major pneumococcal protein antigens in relation to
nasopharyngeal carriage in early infancy before a pneumococcal conjugate vaccine is given.
We hypothesized that the risk of nasopharyngeal carriage by the pneumococcus within the
first eight weeks of life would be associated with the amount and kinetics of antibodies against
the pneumococcal protein antigens transferred to the infants from their mothers.
Subjects and methods
Study setting and population
This was a longitudinal, cohort study conducted at two health centres in The Gambia—Faji-
kunda and Brikama. These are both peri-urban towns in the Western Region, within 20 and
30 km respectively from the capital Banjul, and with a population of approximately 150,000.
This area has a long dry season from December to July and a shorter rainy season. Malaria
infection is uncommon in this peri-urban area. Immunization coverage in The Gambia for
third dose of diphtheria, pertussis and tetanus vaccines (DPT3) has been above 80% for over a
decade. The seven-valent PCV (PCV7) was introduced into the Expanded Programme of
Immunisation (EPI) schedule of The Gambia in 2009 and replaced by PCV13 in 2011. PCV13
is given along with other childhood vaccines DPT, Hib and OPV at 2, 3 and 4 months of age.
The study described in this paper was conducted between 2013 and 2014.
Healthy pregnant women in their third trimester attending the antenatal clinic in either of
the two study health centres were invited to join the study. Written informed consent was
obtained. Procedures involved in the study, as well as consent, were reconfirmed on presenta-
tion at the delivery room.
Sample collection times
Nasopharyngeal swabs (NPS) were taken from both mother and child in the delivery room,
and during follow-up visits at home every two weeks for the first eight weeks of life, coinciding
with the period before the infants received their first dose of PCV. 2ml heparinised blood sam-
ples were collected from the mother and from the umbilical cord at delivery. Thereafter, blood
samples were collected from both mother and baby four and eight weeks after delivery. The
blood and NPS samples were transported to the laboratory within six hours of collection. Field
workers were trained in the procedure for obtaining NPS and venous blood samples. The
study was approved by the joint Gambia Government/MRC Ethics Committee.
Nasopharyngeal swab collection and isolation of the pneumococcus
NPS were collected as previously described.[23] Briefly, a Dacron-tipped swab (Corsham, UK)
was inserted gently through the nostril and left to soak for about 5 seconds in the nasopharynx,
rotated gently and removed. After the NPS had been obtained, the tip was excised immediately
and placed in a cryovial containing 1ml skim milk-tryptone-glucose-glycerol (STGG) medium,
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and placed in a cold box with ice-packs. NPS-STGG specimens were then transported within
six hours to the laboratory at the MRC Unit at Fajara, and stored at– 70˚C until analyzed.
For culture of S. pneumoniae from the NPS, the specimens were thawed to room tempera-
ture, vortexed and 50 microliters of sample plated onto gentamicin supplemented, sheep blood
agar (GBA) (BioMerieux, USA) and incubated overnight at 37˚C in 5% CO2. Morphologically
distinct alpha-hemolytic colonies were sub-cultured onto plain sheep blood agar. S. pneumo-
niae was identified by colonial morphology and optochin disc susceptibility (Oxoid, UK). Iso-
lates with reduced optochin disc zone diameters (7–13 mm) were confirmed as S. pneumoniae;
pure isolates were stored at -70˚C.
For the isolation of S. pneumoniae by molecular technique, DNA samples were extracted
from the thawed NPS-STGG specimens. Extraction was done using a QIAamp DNA Blood
Mini kit (Qiagen, Switzerland) according to manufacturer’s instructions. Briefly, 200μl of NPS
sample was resuspended in 50μl of digestion buffer (50 mM Tris-HCl [pH 8.5], 1 mM EDTA,
0.5% sodium dodecyl sulfate, 200 mg of proteinase K per ml), the suspension was incubated
on a shaker for 1h at 37˚C. 100ul AE buffer was then added to elute the DNA, which was stored
at -80˚C until analysis by RT-PCR.
Real-time Polymerase Chain Reaction (RT-PCR)
The RT-PCR assay was carried out in a final 25μl reaction volume and was performed using
TaqMan Universal Master Mix (Applied Biosystems, USA) with 2.5μl of DNA. The sequence
for the real-time primers and probe used were as previously published and derived from the
autolysis gene (lytA) of S. pneumoniae (Forward: 50-ACG CAA TCT AGC AGA TGA AGC-30,
Reverse: TCG 50-TGC GTT TTA ATT CCA GCT-30, probe: 50-FAM-GCCGAAAACGCTTGA
TACAGGGAG-30-BHQ1). [24] The PCR assay was run using the Corbett Rotor-Gene 6000
(Qiagen, Belgium) with the following cycling parameters: 50˚C for 2 min, 95˚C for 10 min, fol-
lowed by 45 cycles of 15s at 95˚C and 1 min at 60˚C. Pneumococcal colonization density was
determined through the creation of standard curves using 10-fold serial dilutions of an in-
house concentrated DNA from a purified S. pneumoniae strain with calculation of pathogen
density (copies/milliliter) from the sample cycle threshold (Ct) values as previously described.
[25] Amplification data were analyzed by instrument software (Rotor-Gene software series
1.7). Cycle threshold (Ct) values40 and>40 were considered positive and negative
respectively.
Immunoassay for antibodies against pneumococcal protein antigens
Serum was separated from venous and cord blood samples and stored at -20˚C until analyzed.
Antibodies against PspA, rPly and CbpA were measured using in-house enzyme-linked immu-
nosorbent assays (ELISAs). Ninety-six well microtiter plates (Maxisorp Nunc, Denmark) were
individually coated with 50μl/well of 5μg/ml for CbpA, PspA, and rPly (all kindly provided by
Prof. James Paton, Adelaide University, Australia) in phosphate-buffered saline (PBS) and
incubated overnight at 4˚C. Plates were then washed twice with PBS Tween 20 (Sigma, USA)
and blocked with 10% Fetal Bovine Serum (FBS) in PBS for 1h at 37˚C. Subgam (Bio Products
Laboratory Limited, UK) which contains known concentrations in mg/ml of IgG antibody
titers to Ply, PspA, and CbpA, was used as the standard, starting with a 1/500 dilution that was
assigned an antibody titer of 2000ug/ml, for each of the protein antigens. Serial two-fold dilu-
tions of the standard were made in blocking buffer. Serum samples were diluted 1:8 in block-
ing buffer (10% FBS), and 50μl/well of serum samples and standards were added to
appropriate wells in duplicate and incubated for 90min. at 150 rpm at room temperature. Fol-
lowing a wash step, anti-human IgG alkaline phosphatase conjugate diluted 1:2000 in blocking
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buffer was added and incubated for a further 90 mins. After washing, colour was developed by
adding 50ul per well of enzyme reaction substrate p-Nitrophenyl Phosphate (pNPP sigma,
USA) and incubated in the dark at room temperature for a final 30mins. The plate was then
read at 405nm on a Spectramax plate reader with Softmax Pro software (Molecular Devices,
USA).
Statistical analysis
PCR was used as the main assay for assessing carriage of S. pneumoniae. However, for two
mothers’ and four infants’ PCR results were missing so culture results were used for carriage.
There was no positive culture that was PCR negative; there were five PCR positive and culture
negative results. Therefore, nasopharyngeal carriage was defined as isolation of S. pneumoniae
by PCR or by culture when the PCR result was missing. Continuous variables were log-trans-
formed prior to analysis. Nasopharyngeal carriage was analyzed using a mixed effects logistic
regression to account for correlation across time points. Mothers’ carriage and infants’ bacte-
rial densities were also compared at each time point using Wilcoxon signed-ranks test. Mother
and infant antibody concentrations were analyzed using Wilcoxon signed-ranks test at birth.
A random-slope linear regression model with Kenward-Roger’s adjustment [26] was fitted to
compare the infants’ antibody concentrations between carriers and non-carriers across time
points and to assess the effect of maternal’ antibody concentrations on infants’ at birth. These
effects were adjusted for mothers’ nasopharyngeal carriage and age, as well as infants’ gender,
health facility of birth and infants’ antibiotics uptake. A joint model allowing for endogeneity
as suggested by Skrondal and Rabe-Hesketh [27] was used to assess the effect of past infants’
nasopharyngeal carriage status on their future carriage status as well as the association between
their antibody concentrations and carriage status. Finally, the effect of infants past nasopha-
ryngeal carriage and antibodies concentrations on their future antibodies concentrations
against CbpA, PspA and rPly was assessed using structural equation modeling [28]. Raw data is
provided in S1 Table.
Results
Study population
One hundred and twenty pregnant women were enrolled into the study following written
informed consent, 67 of these were seen at Brikama health centre while the rest were from the
Fajikunda health centre (Table 1). There was no difference in mother’s age at delivery between
health centres (median (IQR): 27 years (22–31) at Brikama health centre and 26 years (23–29)
at Fajikunda health centre; p = 0.50). All study infants were full term babies; there was no dif-
ference in gender distribution between the health centres (p = 0.15). The median (IQR) birth
weight was 3.1 kg (2.8–3.4) and 3.3 kg (3.0–3.5) in Brikama and Fajikunda health centres
respectively, with some evidence of a difference in the birth weight between the health centres
(p = 0.02) but there was no difference in the birth weight between boys and girls (p = 0.22).
Concentrations of antibodies to CbpA, PspA and rPly in mothers and
infants
There was no difference in the concentrations of antibodies against the three protein antigens
in the mothers or infants between the two health centres (Table 1). At birth, antibody concen-
trations against CbpA antigen in the mothers and in cord blood were comparable (p = 0.26;
Fig 1) with a mean (SD) log-antibody concentration of 8.8 (0.8) and 8.9 (0.8) in mothers and
infants respectively. Likewise, the antibody concentrations against rPly antigen in mothers
Relationship between antibodies against pneumococcal proteins and nasopharyngeal carriage
PLOS ONE | https://doi.org/10.1371/journal.pone.0185824 October 5, 2017 5 / 15
Table 1. Characteristics of mothers and children at delivery or birth by health centre.
Total
(n = 120)
Brikama centre
(n = 67)
Fajikunda centre
(n = 53)
p
Mother’s age (years), median (IQR) 26 (22–30) 27 (22–31) 26 (23–29) 0.50 a
Birth weight in Kg, median (IQR) 3.2 (3–3.5) 3.1 (2.8–3.4) 3.3 (3–3.5) 0.02 a
Child gender, n (%)
Male 59 (49.2) 29 (43.3) 30 (56.6) 0.15 b
Female 61 (50.8) 38 (56.7) 23 (43.4)
Mothers’ baseline antibody concentrations, median (IQR)
Against CbpA 5790 (3987–10868) 6406 (4215–11461) 4946 (3340–9626) 0.04 a
Against PspA 27373 (19126–59020) 32205 (21728–55839) 23620 (18450–60517) 0.19 a
Against rPly 5666 (3504–10384) 4930 (3195–10210) 7623 (3922–11525) 0.09 a
Infants’ baseline antibody concentrations, median (IQR)
Against CbpA 6021 (4241–10919) 6357 (4410–11016) 5214 (3660–10697) 0.17 a
Against PspA 5141 (3208–7813) 4957 (3107–7029) 5420 (3438–9997) 0.24 a
Against rPly 6075 (3448–9713) 6771 (3343–9899) 5974 (3781–9680) 0.67 a
a Wilcoxon signed-ranks test.
b Chi-square test.
https://doi.org/10.1371/journal.pone.0185824.t001
Fig 1. Concentration of antibodies against CbpA, PspA and rPly in mothers’ (closed circles) and cord
blood (open circles) at birth. The horizontal black lines represent the average log-plasma antibody
concentrations. The p values indicate the difference between the average antibody concentration for the
specific pneumococcal antigen between mothers’ venous blood and infants’ cord blood at birth.
https://doi.org/10.1371/journal.pone.0185824.g001
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(mean (SD): 8.8 (0.9)) and children (mean (SD): 8.7 (1.0)) were similar (p = 0.70). However,
the antibody concentration against PspA protein antigen was higher in mothers compared to
infants (mean (SD): 10.3 (0.9) vs. 8.7 (1.0); p<0.0001). There was strong evidence that the
higher the mothers’ antibody concentrations against antigens CbpA and rPly were at delivery,
the higher those antibodies’ concentrations were in the infant at birth (p< 0.001 for each anti-
gen (Table 2). However, no association was found in the antibody concentration against PspA
at birth between mother’s and infants’ (p = 0.91). In contrast to the situation at birth, there was
no association between mothers’ antibody concentrations against CbpA at delivery and infants’
antibody concentrations against CbpA at four or eight weeks after birth (p = 0.97 and p = 0.57
respectively). As opposed to CbpA, the concentration of antibody against PspA in mothers at
delivery was positively associated with infants’ antibody concentration against PspA at four
weeks after birth (change per unit increase in mothers’ antibody concentration at delivery:
0.48 [95% CI: 0.31–0.65], p<0.0001) and eight weeks (change per unit increase in mothers’
antibody concentration at delivery: 0.40 [95% CI: 0.22–0.57], p<0.0001). In the case of rPly,
there was strong positive evidence of an association between mothers’ antibody concentration
against rPly at delivery and that of the infants at four and eight weeks after birth (p<0.0001
and p = 0.001 respectively). However, the strength of this association with respect to rPly
decreased at four weeks after birth (change per unit increase in mothers’ antibody concentra-
tion at delivery: 0.55 [95% CI: 0.36–0.75], p<0.0001) and at eight weeks (change per unit
increase in mothers’ antibody concentration at delivery: 0.32 [95% CI: 0.13–0.52], p = 0.001)
compared to the change per unit increase at birth (0.89 [95% CI: 0.72–1.06]).
Nasopharyngeal carriage in mothers and infants
The nasopharyngeal carriage of S. pneumoniae in mothers and infants using either PCR alone
or PCR and culture when PCR result was missing was similar (Table 3). The nasopharyngeal
carriage was low in infants at birth as expected, stable over the first four weeks after delivery,
increased at 6 weeks and decreased at 8 weeks (Table 3). In addition, there was a difference in
pneumococcal colonization density across time points in infants (p<0.0001, Fig 2A). A con-
trasts analysis with Sidak’s multiple testing adjustment showed a difference in pneumococcal
colonization density between two and four weeks (p = 0.002) but no difference between zero
and two weeks (p = 0.84), between four and six weeks (p = 0.42) and between six and eight
weeks (p = 0.53). As opposed to infants, mothers’ pneumococcal colonization density
remained similar over the study period (p = 0.40, Fig 2B). Mothers’ pneumococcal coloniza-
tion density at delivery were significantly higher than those of the infants at birth (p = 0.0004),
but not at two weeks (p = 0.11). Pneumococcal colonization density were higher in infants
compared to the mothers at four weeks (p = 0.009), six weeks (p = 0.002) and eight weeks
(p<0.0001). Infants’ nasopharyngeal carriage four weeks earlier and their current carriage sta-
tus were not associated (p = 0.28, Table 4). However, the odds of carriage in infants was 6.2
times (95% CI: 2.0–18.9) higher when their mothers were carriers within the same week than
when they were not a carrier (p = 0.001). No association between antibiotics uptake and naso-
pharyngeal carriage in infants was found (p = 0.57).
The relationship of the antibody concentrations to nasopharyngeal
carriage in infants
The ability of antibodies against the pneumococcal proteins to protect against nasopharyngeal
carriage was addressed by comparing the concentrations of those that carried with those that
did not at the three time points that the antibodies were measured. This was analyzed using
dynamic logistic regression with joint working models allowing for endogeneity of time-
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varying covariates (Table 4). Log-antibody concentrations against CbpA, PspA and rPly in
infants were analysed using a linear dynamic panel data model (Table 4). A negative associa-
tion between the current antibody concentration against CbpA antigen and nasopharyngeal
carriage in infants (p = 0.03, Table 4) was found [OR (95% CI): 0.49 (0.26–0.92]. In contrast
there was no evidence of association between infants antibody concentrations and their chance
of carriage for PspA [OR (95% CI): 1.00 (0.42–2.37), p = 0.99] or rPly antibodies [OR (95%
CI): 1.41 (0.72–2.75), p = 0.32].
The log-antibody concentration against CbpA was higher by 0.27 (95% CI: 0.01; 0.53,
p = 0.04, Table 5) in infants who were carriers four weeks previously compared to those who
Table 2. Effects of mother’s log-antibody concentrations against CbpA, PspA and rPly at delivery on infant’s log-antibody concentrations and dif-
ference in infant’s antibody concentrations between carriers and non-carriers at birth, 4 and 8 weeks.
Main explanatory variables Effect on infant’s log-
antibody concentration
against CbpA
Effect on infant’s log-
antibody concentration
against PspA
Effect on infant’s log-
antibody concentration
against rPly
Change (95%
CI)
p Change (95%
CI)
p Change (95%
CI)
p
Mother’s log-antibody concentrations against corresponding antigen
at delivery a
At birth 0.75 (0.56; 0.93) <0.0001 0.01 (-0.16;
0.18)
0.91 0.89 (0.72;
1.06)
<0.0001
4 weeks 0.004 (-0.20;
0.20)
0.97 0.48 (0.31;
0.65)
<0.0001 0.55 (0.36;
0.75)
<0.0001
8 weeks 0.06 (-0.14;
0.26)
0.57 0.40 (0.22;
0.57)
<0.0001 0.32 (0.13;
0.52)
0.001
Infant’s log-antibody concentration against CbpA - - 0.27 (0.16;
0.38)
<0.0001 0.01 (-0.11;
0.13)
0.89
Infant’s log-antibody concentration against PspA 0.20 (0.10; 0.30) <0.0001 - - 0.13 (0.02;
0.24)
0.03
Infant’s log-antibody concentration against rPly -0.01 (-0.11;
0.09)
0.81 0.12 (0.01;
0.22)
0.03 - -
Infant’s carriage status (ref: Non-carrier)
Carrier -0.12 (-0.30;
0.05)
0.17 0.14 (-0.04;
0.33)
0.13 0.02 (-0.18;
0.21)
0.86
Mother’s carriage status (ref: Non-carrier)
Carrier -0.01 (-0.18;
0.17)
0.94 0.05 (-0.13;
0.24)
0.58 -0.07 (-0.26;
0.12)
0.48
a Corresponding antigen is: CbpA, PspA and rPly if the outcome is infant’s log-antibody concentration against CbpA, PspA and rPly, respectively.
All reported effects were also adjusted for mother’s age, infant’s gender, infant’s uptake of antibiotics and birth health centre.
https://doi.org/10.1371/journal.pone.0185824.t002
Table 3. Nasopharyngeal carriage rate and 95% CI in mothers and infants at birth, 2, 4, 6 and 8 weeks.
Time after delivery Risk (95% CI) in mothers Risk (95% CI) in infants
PCR alone PCR or culture a PCR alone PCR or culture a
At birth 53.3 (16.9–86.5) 53.3 (16.9–86.5) 35.4 (8.7–76.0) 34.7 (8.4–75.5)
2 weeks 57.57 (19.5–88.5) 57.7 (19.5–88.5) 41.8 (11.1–80.5) 41.7 (11.0–80.5)
4 weeks 51.6 (15.9–85.7) 51.6 (15.9–85.7) 57.9 (19.3–88.8) 57.9 (19.2–88.8)
6 weeks 61.8 (22.2–90.2) 61.7 (22.1–90.1) 68.3 (26.9–92.6) 67.7 (26.3–92.5)
8 weeks 45.3 (12.8–82.4) 45.3 (12.8–82.4) 69.9 (28.3–93.2) 69.3 (27.7–93.0)
a Definition of nasopharyngeal carriage used in our study: isolation of Streptococcus pneumoniae by PCR or by culture when PCR result was not available.
https://doi.org/10.1371/journal.pone.0185824.t003
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were non-carriers. No association was found between infants’ nasopharyngeal carriage four
weeks earlier and their current log-antibodies concentration against PspA (p = 0.22) or rPly
(p = 0.70). There was a strong positive association between log-antibodies concentration
against rPly in infants four weeks earlier and their log-antibodies concentration against rPly
four weeks later (change per unit increase: 0.31 (95% CI: 0.09; 0.52), p = 0.005) but this associa-
tion was not found for CbpA (p = 0.79) or PspA (p = 0.76). The results from all analyses
Fig 2. The density of S.pneumoniae in the nasopharynx in the first eight weeks after birth in infants (A) and
the first eight weeks after delivery in mothers (B). The horizontal black lines represent the average Real-time Ct
value, which is inversely correlated with the density. The p value indicates the evidence of variation of the density over
the eight week period.
https://doi.org/10.1371/journal.pone.0185824.g002
Table 4. Dynamic of nasopharyngeal carriage and influence of concentration of antibodies against
CbpA, PspA and rPly in infants.
Main explanatory variables a Effect on infant’s current
nasopharyngeal carriage
OR (95% CI) P
Infant’s carriage status four weeks earlier (ref: Non-carrier)
Carrier 0.41 (0.08–2.09) 0.28
Infant’s current log-antibody concentration against CbpA 0.49 (0.26–0.92) 0.03
Infant’s current log-antibody concentration against PspA 1.00 (0.42–2.37) 0.99
Infant’s current log-antibody concentration against rPly 1.41 (0.72–2.75) 0.32
Mother’s current carriage status (ref: Non-carrier)
Carrier 6.20 (2.03–18.9) 0.001
Infant’s current uptake of antibiotics (ref: No)
Yes 1.71 (0.27–10.8) 0.57
a Time-invariant variables such as infant’s gender, birth health centre, mother’s age, mother’s log-antibody
concentrations against CbpA, PspA and rPly at delivery were also included in the models
https://doi.org/10.1371/journal.pone.0185824.t004
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presented above did not change when nasopharyngeal carriage in infants or mothers was
defined using the PCR assay alone.
Discussion
This study evaluated nasopharyngeal colonization with S. pneumoniae and its relationship to
concentrations of antibodies against three major pneumococcal protein antigens in the first
two months of life, the period before the first dose of PCV was given, in two peri-urban com-
munities in The Gambia. The proportion of infants who carried the pneumococcus as well as
the bacterial density of S. pneumoniae in their nasopharynx increased progressively from birth
to the age of eight weeks, while prevalence and density in the mothers remained the same. The
concentrations of antibodies against the pneumococcal proteins in the cord blood were high
and comparable to those in the mothers at birth. The concentrations of antibodies against
CbpA and rPly declined with time while the opposite was the case for antibodies against PspA.
Higher antibody concentrations to CbpA, but not PspA and rPly, were associated with reduced
nasopharyngeal carriage of S. pneumoniae in infants.
The possibility of direct protection of young infants, who are at high risk of invasive pneu-
mococcal disease, by the pneumococcal IgG antibodies acquired from maternal-fetal transfer
has led to consideration of immunizing pregnant mothers. [29] A number of factors including
hypergammaglobulinaemia, HIV/AIDs and malaria affect transplacental transfer of antibodies
[30, 31]. However, understanding of the factors that influence mother-to-child transfer of anti-
bodies against pneumococcal antigens is limited. Our data show that maternal antibodies are
passed through the placenta to newborns in similar concentrations for CbpA and rPly but not
Table 5. Dynamic relationship between concentration of antibodies against CbpA, PspA and rPly and
nasopharyngeal carriage in infants.
Main explanatory variables a Infant’s current
log-antibody
concentration
against CbpA
Infant’s current
log-antibody
concentration
against PspA
Infant’s current
log-antibody
concentration rPly
Effect (95%
CI)
P Effect (95%
CI)
p Effect (95%
CI)
p
Infant’s carriage status four weeks earlier
(ref: Non-carrier)
Carrier 0.27 (0.01;
0.53)
0.04 -0.12 (-0.31;
0.07)
0.22 0.05 (-0.19;
0.28)
0.70
Infant’s log-antibody concentration
against CbpA four weeks earlier
0.03 (-0.20;
0.26)
0.79 -0.07 (-0.24;
0.10)
0.39 0.24 (-0.45;
0.03)
0.02
Infant’s log-antibody concentration
against PspA four weeks earlier
-0.24 (-0.38;
-0.09)
0.001 -0.02 (-0.15;
0.11)
0.76 -0.02 (-0.15;
0.12)
0.82
Infant’s log-antibody concentration
against rPly four weeks earlier
-0.17 (-0.42;
0.09)
0.20 -0.19(-0.36;
-0.02)
0.03 0.31 (0.09;
0.52)
0.005
Mother’s current carriage status (ref:
Non-carrier)
Carrier 0.20 (-0.08;
0.48)
0.17 0.13 (-0.12;
0.39)
0.31 0.18 (-0.08;
0.48)
0.17
Infant’s current uptake of antibiotics (ref:
No)
Yes 0.22 (-0.22;
0.67)
0.32 -0.06 (-0.45;
0.32)
0.75 0.05 (-0.42;
0.52)
0.83
a Time-invariant variables such as infant’s gender, birth health centre, mother’s age, mother’s log-antibody
concentrations against CbpA, PspA and rPly at delivery were also included in the models.
https://doi.org/10.1371/journal.pone.0185824.t005
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for PspA antibodies which were lower in infants than in their mothers. Although protective
protein antibody concentrations are yet to be determined, our findings imply that antibodies
against these antigens that might be induced in mothers during pregnancy by vaccination will
be passed on to the newborns. However there is a risk that high concentrations of these anti-
bodies in infants could limit responses to these protein antigens if given as vaccines in early
infancy, as shown for other vaccines such as tetanus toxoid and measles [32–34].
As expected, the proportion of infants from whom a pneumococcus was isolated from the
nasopharynx was low at birth and increased with age. This pattern of nasopharyngeal carriage
is similar to that observed in rural Gambia villages [35]. However, the proportion of infants
that carried in the current study was lower than that recorded in the previous rural study [33,
36]. This could be due to the fact that living conditions in the peri-urban area where our study
was conducted have fewer risk factors associated with carriage compared to the rural areas. It
could also be due to the indirect effect on nasopharyngeal carriage of PCV that was introduced
into the routine immunization programme of The Gambia three years before our study was
conducted as deployment of PCVs in infants can be associated with an indirect effect against
pneumococcal carriage [1,37,38].
The increase in the pneumococcal colonization density with age in the infants within the
first 8 weeks of life is likely to be due to cumulative acquisition of pneumococci of the same or
different serotypes with increasing exposure to the environment with time. The increasing
proportions of children that carry S. pneumoniae, coupled with the increasing density with age
are likely to contribute to the increased incidence of invasive pneumococcal diseases in early
infancy. Indeed, S. pneumoniae has been shown to colonize the nasopharynx for several weeks
without any diseases, but IPD may ensue under conditions that are associated with an increase
in bacterial density in the nasopharynx [39,40]. A previous study in The Gambia found a
decrease in bacterial density and carriage rate with age, but this applied to an older age group
[41]. It is possible that the pneumococcal colonization density and carriage rate of the infants
in our study would reach a maximum shortly after observations were concluded and then
begin to decline as they acquired immunity following the recurrent exposures and carriage
with time [42, 43].
There was evidence that the higher the concentration of antibodies against CbpA in early
infancy, the lower the chance of carriage in the infants. We could not determine a concentra-
tion of antibody against CbpA that could be used as a marker of protection, due in part to the
relatively small sample size of this study. The lack of evidence for reduction in the risk of car-
riage by antibodies against PspA and rPly is similar to other studies [24,44]. This could be due
to the fact that these antigens do not exert their effect on nasopharyngeal carriage through
antibodies but by T cells, as previously described [45]. There was tendency for a higher con-
centration of antibodies against PspA to be associated with a higher carriage perhaps because
antibodies against PspA are not able to protect against carriage and are an indicator of a risk
factor for exposure. [46].
In conclusion, our study found that the naturally induced antibodies against three pneumo-
coccal protein antigens were transferred from mother to infant. The proportion of infants with
nasopharyngeal carriage and bacterial density of S. pneumoniae increased with age within the
first eight weeks of life. Higher concentrations of antibodies against CbpA, but not PspA and
rPly, were associated with a reduced risk of nasopharyngeal carriage of S. pneumoniae in infants.
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